基本信息
文件名称:racemic-Lisofylline-d4-racemic-Lisophylline-d-sub-4-sub-生命科学试剂-MCE.pdf
文件大小:466.71 KB
总页数:1 页
更新时间:2025-05-21
总字数:约2.64千字
文档摘要

Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

(±)-Lisofylline-d4

Cat.No.:HY-126042S4

CASNo.:1185879-05-3

Synonyms:(±)-Lisophylline-d4

分?式:C??H??D?N?O?

分?量:284.35

作?靶点:Isotope-LabeledCompounds;InterleukinRelated

作?通路:Others;Immunology/Inflammation

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性(±)-Lisofylline-d4((±)-Lisophylline-d4)是氘代标记的(±)-Lisofylline.(±)-Lisofylline((±)-Lisophylline)为

Lisofylline的外消旋体。Lisofylline抑制磷脂酸和游离脂肪酸的?成,在氧化性组织损伤、癌症化疗和实验性

败?症中,Lisofylline阻?促炎细胞因?的释放。Lisofylline可?于1型糖尿病研究。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumSubstitutiononthePharmacokineticsofPharmaceuticals.AnnPharmacother.2019;5